Arcturus Therapeutics Holdings Inc. Common Stock
ARCT Real Time Price USDRecent trades of ARCT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ARCT's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$20,000 Jul 17, 2021 Issue: Health Issues Medicare/Medicaid
-
$20,000 Apr 19, 2021 Issue: Health Issues Medicare/Medicaid
-
$90,000 Jan 19, 2021 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
-
$100,000 Oct 25, 2020 Issue: Medical/Disease Research/Clinical Labs
-
$80,000 Oct 19, 2020 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
-
$30,000 Apr 17, 2020 Issue: Medical/Disease Research/Clinical Labs
Estimated quarterly lobbying spending
ARCT Revenue by Segment or Geography
New patents grants
-
Patent Title: Method of making lipid-encapsulated rna nanoparticles Feb. 11, 2025
-
Patent Title: Coronavirus vaccine compositions and methods Feb. 11, 2025
-
Patent Title: Method of lyophilizing lipid nanoparticles Dec. 31, 2024
-
Patent Title: Lipid particles for nucleic acid delivery Sep. 10, 2024
-
Patent Title: Synthetic transfer rna with extended anticodon loop Sep. 03, 2024
-
Patent Title: Nucleic acids and methods of treatment for cystic fibrosis Aug. 27, 2024
-
Patent Title: Compositions and methods for treating phenylketonuria Mar. 26, 2024
-
Patent Title: Translatable molecules and synthesis thereof Mar. 26, 2024
-
Patent Title: Lipid nanoparticles encapsulation of large rna Mar. 26, 2024
-
Patent Title: Compositions and methods for inducing immune responses Sep. 19, 2023
-
Patent Title: Coronavirus vaccine compositions and methods Sep. 05, 2023
-
Patent Title: Method of making lipid-encapsulated rna nanoparticles Aug. 29, 2023
-
Patent Title: Molecules and agents for treating hepatitis b virus Jun. 27, 2023
-
Patent Title: Compositions and methods for treating ornithine transcarbamylase deficiency Jun. 27, 2023
-
Patent Title: Ionizable cationic lipid for rna delivery Oct. 04, 2022
-
Patent Title: Synthetic transfer rna with extended anticodon loop Sep. 06, 2022
-
Patent Title: Translatable molecules and synthesis thereof Aug. 09, 2022
-
Patent Title: Synthesis and structure of high potency rna therapeutics May. 25, 2021
-
Patent Title: Ionizable cationic lipid for rna delivery Apr. 20, 2021
-
Patent Title: Compositions and agents against hepatitis b virus and uses thereof Mar. 30, 2021
-
Patent Title: Ionizable cationic lipid for rna delivery Mar. 30, 2021
-
Patent Title: Messenger una molecules and uses thereof Oct. 27, 2020
-
Patent Title: Method of synthesis of an ionizable cationic lipid Sep. 22, 2020
-
Patent Title: Acyl-amino-lna and/or hydrocarbyl-amino-lna oligonucleotides Aug. 04, 2020
-
Patent Title: Una oligomers having reduced off-target effects in gene silencing Jun. 16, 2020
-
Patent Title: Ionizable cationic lipid for rna delivery Feb. 11, 2020
-
Patent Title: Ionizable cationic lipid for rna delivery Jan. 07, 2020
-
Patent Title: Therapeutic una oligomers and uses thereof Dec. 31, 2019
-
Patent Title: Trinucleotide mrna cap analogs Nov. 26, 2019
-
Patent Title: Una oligomers for therapeutics with prolonged stability Oct. 29, 2019
-
Patent Title: Una oligomers and compositions for treating amyloidosis Sep. 24, 2019
-
Patent Title: Ionizable cationic lipid for rna delivery Sep. 03, 2019
-
Patent Title: Ionizable cationic lipid for rna delivery Aug. 20, 2019
-
Patent Title: Allele selective gene editing and uses thereof Aug. 06, 2019
-
Patent Title: Aromatic ionizable cationic lipid Mar. 19, 2019
-
Patent Title: Ionizable cationic lipid for rna delivery Mar. 12, 2019
-
Patent Title: Transthyretin allele selective una oligomers for gene silencing May. 29, 2018
-
Patent Title: Multiligand agent for drug delivery May. 08, 2018
-
Patent Title: Ionizable cationic lipid for rna delivery Apr. 24, 2018
-
Patent Title: Una single stranded oligomers for therapeutics Apr. 17, 2018
-
Patent Title: Ionizable cationic lipid for rna delivery Feb. 20, 2018
-
Patent Title: Formulations for treating amyloidosis Jan. 02, 2018
-
Patent Title: Ionizable cationic lipid for rna delivery Dec. 26, 2017
-
Patent Title: Aromatic ionizable cationic lipid Dec. 05, 2017
-
Patent Title: Ionizable cationic lipid for rna delivery Jun. 06, 2017
-
Patent Title: Ionizable cationic lipid for rna delivery Mar. 14, 2017
-
Patent Title: Lipid particles with asymmetric cationic lipids for rna delivery Feb. 28, 2017
-
Patent Title: Ionizable cationic lipid for rna delivery Feb. 14, 2017
-
Patent Title: Asymmetric ionizable cationic lipid for rna delivery Jun. 14, 2016
-
Patent Title: Una oligomer structures for therapeutic agents May. 17, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to ARCT
Recent picks made for ARCT stock on CNBC
ETFs with the largest estimated holdings in ARCT
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ARCT stock a Buy, Sell, or Hold?
- What is the price target for $ARCT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ARCT stock?
- Who owns the most shares of $ARCT stock?
- What funds own $ARCT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ARCT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.